 Medroxyprogesterone acetate lowers corticotropin cortisol anterior pituitary responsiveness human corticotropin factor endocrine action medroxyprogesterone acetate MPA glucocorticoid-like nature clinical observation MPA life quality overall well-being patients advanced breast cancer renal carcinoma prostatic carcinoma uterine adenocarcinoma authors MPA endocrine action administration human corticotropin factor hCRF assay patients advanced breast cancer renal cell carcinoma initiation oral high-dose MPA treatment mg MPA days therapy curves corticotropin beta-endorphin cortisol responses tumor patients initiation MPA treatment parallel curves healthy control group probands equal conditions respective hormone levels patients malignant disorders MPA administration basal hormone levels comparable values healthy controls conclusion MPA suprapituitary level pituitary responsiveness MPA treatment MPA hormonal stress state patients malignant tumors normal